clinical trial · NCT07562581
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·phase2·recruiting·n = 48
Non-small Cell Lung CanerKRAS-mutatedMetastasisPrevious Treamtedluvometinib + anlotinibluvometinib + anlotinib
brief summary
Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
started
Jun 15, 2026
primary completion
Jun 1, 2029
completion
Jun 1, 2030
last updated
Sep 2, 2026
official title
A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol